| Literature DB >> 33073221 |
Suddha Sourav1, Davide Bottari1,2, Idris Shareef3, Ramesh Kekunnaya3, Brigitte Röder1.
Abstract
BACKGROUND: Untreated congenital blindness through cataracts leads to lasting visual brain system changes, including substantial alterations of extrastriate visual areas. Consequently, late-treated individuals (> 5 months of age) with dense congenital bilateral cataracts (CC) exhibit poorer visual function recovery compared to individuals with bilateral developmental cataracts (DC). Reliable methods to differentiate between patients with congenital and developmental cataracts are often lacking, impeding efficient rehabilitation management and introducing confounds in clinical and basic research on recovery prognosis and optimal timing of surgery. A persistent reduction of the P1 wave of visual event-related potentials (VERPs), associated with extrastriate visual cortical activity, has been reported in CC but not in DC individuals. Using two experiments, this study developed and validated P1-based biomarkers for diagnosing a history of congenital blindness in cataract-reversal individuals.Entities:
Keywords: Biomarker; Cataract; Congenital cataract; Extrastriate processing; Pediatric cataract; Sight recovery; Visual deprivation
Year: 2020 PMID: 33073221 PMCID: PMC7548424 DOI: 10.1016/j.eclinm.2020.100559
Source DB: PubMed Journal: EClinicalMedicine ISSN: 2589-5370
Fig. 1A. Standards for Reporting of Diagnostic Accuracy (STARD) flow diagram for P1 amplitude based diagnostic biomarker development (experiment 1), and B. Validation in experiment 2 with classification thresholds developed from experiment 1. C. Venn diagram showing participant overlap in the two experiments (CC: Participants with a history of congenital dense bilateral cataracts and subsequent vision restoration, DC: Participants with a history of bilateral developmental cataracts and subsequent vision restoration).
Fig. 2Visual stimulus locations used in the two experiments. The stimuli were presented randomly and one at a time, with rare vertical gratings serving as behavioral targets.
Fig. 3Development and validation of an electrophysiological biomarker for classifying sight recovered bilateral congenital vs. bilateral developmental cataract individuals. A. Visual event-related potentials (VERPs) to upper visual field stimuli from experiment 1 were used for classifier development. The VERPs at electrode P8 is depicted for all three groups. Shaded colored areas show the standard error of the mean. We first extracted the mean P1 amplitude over a 50 ms time range around the average P1 latency (note that electrodes below the nasion-inion “great circle” are depicted outside the head circumference). Thereafter, we normalized the P1 amplitude over the whole electrode montage and calculated the mean value over the posterior electrodes as a biomarker (Mean posterior P1, MPP1). We created an additional biomarker by employing a linear support vector machine to find the optimum linear coefficients for classifying CC individuals (SVMP1). Receiver operating characteristics analysis was used to find optimum threshold values, maximizing the Youden's J parameter. B. Validation of the classification algorithm. VERPs to upper visual field stimuli were obtained from a separate experiment using a different viewing distance. The biomarkers MPP1 and SVMP1 for congenital cataract history were obtained for each individual and classification performance was measured using the thresholds obtained from the first experiment.
Fig. 4Development and validation of the P1-based biomarkers for classifying congenital cataract individuals. A. Receiver operating characteristic (ROC) curve from the first experiment involving all three groups classifying CC individuals using the MPP1 marker. B. ROC curve from experiment 1 for the SVMP1 marker. C. Optimal linear weights for the posterior electrodes for SVM-based classification, plotted as a topography (unitless). D. and E. ROC curves for MPP1 and SVMP1 based classification for experiment 2. F. ROC curve for the SVMP1 validation performance in experiment 2 with weights developed from a group of only CC and DC individuals in experiment 1, applied for the combined group of only CC and DC individuals in experiment 2. G. and H. ROC curves for experiment 2 as in panels D. and E., but with only the new CC and DC participants (NCC = 3, NDC = 10, NControl = 29). Each panel displays the areas under the ROC curves (AUCs) and their 95% confidence intervals (CIs). CI bands for sensitivities are depicted as shaded areas (all sensitivity CIs obtained with stratified bootstraps, n = 2000). All ps < .05 for the ROCs. For statistical details see Table 1.
Classifier performance. For the mean posterior P1 (MPP1) and the linear support vector machine based P1 (SVMP1) biomarkers, key classification parameters for the development and validation are shown: Area under the ROC curve (AUC), sensitivity, specificity, and likelihood ratios.
| AUC(95%CI) | Sensitivity | Specificity | Positive Likelihood Ratio | Negative Likelihood Ratio | |
|---|---|---|---|---|---|
| MPP1 | 0.803 (0.627 – 0.979) | 0.769 | 0.846 | 4.99 | 0.27 |
| SVMP1 | 0.929 (0.846 – 1.000) | 0.846 | 0.897 | 8.21 | 0.17 |
| AUC(95%CI) | Sensitivity | Specificity | Positive Likelihood Ratio | Negative Likelihood Ratio | |
| MPP1 | 0.800 (0.641 – 0.960) | 0.643 | 0.909 | 7.07 | 0.39 |
| SVMP1 | 0.883 (0.775 – 0.992) | 0.786 | 0.864 | 5.78 | 0.25 |
| AUC(95%CI) | Sensitivity | Specificity | Positive Likelihood Ratio | Negative Likelihood Ratio | |
| MPP1 | 0.757 (0.568 – 0.946) | 0.643 | 0.800 | 3.22 | 0.45 |
| SVMP1 | 0.852 (0.711 – 0.994) | 0.857 | 0.800 | 4.29 | 0.18 |